The SGD Pharma group and its shareholder JIC, announce an investment of more than 20 million euros to rebuild the furnace and modernize the century-old Sucy-en-Brie site
The Sucy-en-Brie factory, 400 employees, has been dedicated to producing pharmaceutical glass vials and bottles since 1917. The factory supplies syrups, droppers, tablets, injectable and infusion bottles to over 450 customers around the world and cover the following therapeutic areas: oral and parenteral antibiotics, parenteral nutrition, respiratory illness, pain-relievers, anesthetics, and OTC. Every year, Sucy produces number of bottles of Type II & III flint and amber molded glass bottles, making this factory one of the biggest players in the European health care industry. Its 41,000 m² surface includes two furnaces, 8 production lines, connected to ISO 8 clean rooms. The factory operates under the most stringent quality requirements, and is certified ISO 15378 & 50001.
A major investment for the group
The furnace renovation will include, complete rebuilt using the most advanced technologies available on the market to meet our continuous improvement initiatives while significantly reducing our environmental footprint.
Benefits to our customers: a continued improvement in the quality of our products, an increased production flexibility, and a greater adaptation to market needs. This renovation, which will take a few weeks, has been planned for almost a year now which allowed us to optimize the stock management of critical items as well as establishing runs on the second furnace to ensure continuous supply.
SGD Pharma continually strived to strengthen its operational excellence to provide quality products, reliable service to its customers and ensure patient safety.